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Background: Rare rheumatologic diseases are a heterogeneous group of conditions associated with high
morbidity. As a whole group, rare rheumatologic diseases afflict millions of people demanding for effective
therapies. Therefore, we analyzed the impact of the US Orphan Drug Act on the development of anti-rheumatic
orphan drugs.
Methods: Analysis of the FDA database for orphan drug designations.
Results: In the last three decades, out of 77 orphan drug designations, 14 orphan drug approvals were granted
by the FDA for the treatment of rare rheumatologic disorders, i.e. juvenile idiopathic arthritis (N = 5), cryopyrin-
associated periodic syndromes (N = 3), uveitis (N = 3), familial Mediterranean fever (N = 1), anti-neutrophil
cytoplasmic antibody-associated vasculitis (N = 1), and xerostomia and keratoconjunctivitis sicca in Sjögren’s
syndrome (N = 1). Mean time (standard deviation) from designation to approval was 3.9 (2.81) [range 1 … 12] years.
Number of FDA-approved small molecules (N = 6, 43 %) and biologics (N = 8, 57 %) was comparable. Almost every
fifth (19 %) orphan drug designation was withdrawn. Despite the rarity of conditions, 13/14 pivotal studies were
randomized controlled trials.
Conclusions: Orphan drug development is challenging: thirty years of US orphan drug act supported the
development and FDA approval of 14 orphan drug programs with anti-rheumatic compounds for six
rheumatologic diseases.
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Rheumatologic diseases are associated with high morbidity
leading to reduced quality of life, potentially life-long dis-
ability, and premature death. Although rare in individuals,
as a whole group rare rheumatologic disorders afflict a
large group of people [1, 2]. Furthermore, many rare auto-
inflammatory conditions, such as systemic lupus erythema-
todes, dermatomyositis, scleroderma, vasculitis, periodic
fever syndromes, nonbacterial osteomyelitis, or uveitis can* Correspondence: markus.ries@uni-heidelberg.de
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(http://creativecommons.org/publicdomain/zemanifest already in childhood. For example, the prevalence
of juvenile idiopathic arthritis (JIA), having its onset before
16 years of age, varies between 3.8 and 400 per 100,000
[1, 3]. Considering the definition for an orphan disease in
general as a condition affecting less than 7.5 people in
10.000 or less than 200.000 in the US or less than five in
10.000 in the European Union, orphan drug development
is tremendously challenged by small sample sizes [2, 4, 5].
In addition, highly variable manifestations of rheumato-
logic diseases and onset in childhood complicate drug
development. The US Orphan Drug Act was passed in
1983 to stimulate the investment into development of
treatments for rare diseases by granting various incentives,
such as 7 years’ marketing exclusivity, tax credit for 50 %
of clinical trial costs, protocol assistance, Food and Drug
Administration (FDA) fee waiver, and orphan grantsdistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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successful drug development for the treatment of rare
rheumatologic diseases has not been systematically
analyzed. We therefore analyzed how many orphan
drugs were designated and subsequently approved by
the FDA between 1983 and 2013 to treat rare rheu-
matologic diseases.
Methods
Search strategy
For quantitative analysis, we searched the publically avail-
able FDA database for orphan drug designations [6] using
the following disease entities as search terms (terms for
pediatric rheumatologic diseases in alphabetical order [7]):
arthritis, antiphospholipid antibody syndrome, Behçet
syndrome, collagenosis, CREST syndrome (calcinosis,
Raynaud’s phenomenon, esophageal dysmotility, sclero-
dactyly and telangiectasia), childhood and adolescence
arthritis, CAPS (cryopyrin-associated periodic syndromes)
such as CINCA/NOMID (chronic infantile neurologic
cutaneous and articular syndrome/neonatal-onset multi-
system inflammatory disease), MWS (Muckle-Wells
syndrome) or FCAS (familial cold autoinflammatory
syndrome), cutaneous leukocytoclastic vasculitis, dermato-
myositis, diffuse sclerosis, drug induced lupus erythema-
tosus, enthesitis-related arthritis, eosinophilic fasciitis
(Shulman syndrome), eosinophilic granulomatosis with
polyangiitis (Churg-Strauss syndrome), familial cold auto-
inflammatory syndrome, familial Mediterranean fever,
Felty syndrome, granulomatosis with polyangiitis, Hyper
IgD syndrome, idiopathic uveitis, IgA vasculitis (Henoch -
Schönlein purpura), infantile sarcoidosis, isolated sacroilii-
tis, juvenile ankylosing spondylitis, juvenile idiopathic
arthritis, Kawasaki syndrome, limited systemic scleroder-
mia, localized scleroderma, lupus, microscopic polyangii-
tis, mixed connective tissue disease, non-bacterial osteitis,
oligoarthritis, periodic fever syndromes, PFAPA syndrome
(periodic fever, aphthous stomatitis, pharyngitis, adenitis),
polyarteritis nodosa, polymyositis, primary angiitis of
the central nervous system, psoriatic arthritis, relapsing
polychronditis, rheumatoid factor negative polyarthritis,
rheumatoid factor positive polyarthritis, Sharp syndrome,
Sjögren’s syndrome, spondyloarthritis due to chronic
inflammatory intestinal disorders, spondyloarthritis due to
psoriasis, spondylodiscitis, spondylolisthesis, spondylo-
lysis, systemic arthritis, systemic lupus erythematosus,
systemic sclerosis, Takayasu arteritis, transient synovitis,
TRAPS (tumor necrosis factor receptor associated peri-
odic syndrome), undifferentiated juvenile idiopathic
arthritis, and vasculitis (e.g., Anti-neutrophil cytoplasmic
antibody (ANCA) associated vasculitis). Non-English
alphabet letters such as umlaut were searched with alter-
native spellings (e.g., ö was also entered as both o and oe).
Acronyms were searched by both the acronym and the fullwording. Disease terms with more than one word were
searched with the full disease term and with each individ-
ual component of the term, e.g., “juvenile idiopathic arth-
ritis” was searched as “juvenile”, “idiopathic”, “arthritis”,
and “juvenile idiopathic arthritis”. All search results were
subsequently checked for plausibility. All data entries from
1/1/1983 until 12/31/2013 were considered. Original
terms from the FDA orphan drug database or FDA label
were used to describe designated or approved indications
to conform to source data.
Definitions
Identified compounds were categorized either according
to their drug class or pharmacologic category. Within
the respective classification, remaining compounds that
could not be clearly allocated to a particular category
were grouped as others. For classification according to
their drug class, the compounds were accounted as small
molecules or biologics. A small molecule was defined as
a low-weight molecule (typically <1,000 Da) which is
usually derived from chemical synthesis and can be fully
characterized by analytical techniques [8, 9]. In contrast,
biologics are large-molecular weight and structurally
complex proteins that are derived from living cells
through biotechnological processes (e.g., antibody methods,
controlled gene expression or recombinant DNA) [8, 9].
Biologics were further differentiated into antibodies and
fusion proteins. For classification according to pharma-
cologic category, compounds were grouped according to
their mechanism of action which was gained from the
FDA label for approved compounds. For the assessment
of the putative mechanism of action of compounds that
were not approved by the FDA, we started from the desig-
nated indication and selected the most likely mechanism
of action causing the intended effect.
Statistics
Data were analyzed by standard methods of descriptive
statistics with SAS Enterprise Guide version 5.1 (SAS,
Cary, NC, USA). Continuous variables are presented as
means, standard deviations, and ranges. For categorical
variables, N and percentages were calculated. Time-to-
approval was calculated as the time span from orphan
drug designation to FDA approval.
Results
Orphan drug designations
Overall, 77 orphan drug designations were granted for 64
different compounds between 1983 and 2013 (Fig. 1,
Table 1). The first orphan drug designations were granted
in 1986 for two compounds, i.e. guanethidine monosulfate
(for the treatment of moderate to severe reflex sympathetic
dystrophy and causalgia) and dimethyl sulfoxide (for the
treatment of cutaneous manifestations of scleroderma).
Fig. 1 Orphan drugs for rare rheumatologic disorders – number of orphan drug designations (open box) and FDA approvals (black box) per year
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designations per year were granted in 2011 (N = 8). When
analyzed according to drug classes, 33/77 (43 %) designa-
tions were granted for 23 different biologics, 28/77 (36 %)
for 27 different small molecules and 14/77 (18 %)
designations for others representing 12 different com-
pounds (Table 1). With two designations the drug
class of the compounds was unknown (i.e., AI-RSA
and Interleukin-1 Trap). Biologics were further differ-
entiated into chimeric antibodies (4/33), human anti-
bodies (10/33), humanized antibodies (8/33), unspecified
antibodies (2/33) (i.e., human anti-tumor necrosis factor
alpha monoclonal antibody and monoclonal antibody for
immunization against lupus nephritis), fusion proteins
(4/33), and other biologics (5/33) (i.e., anakinra, han-
feron, interferon beta-1a, interleukin-1 receptor antagon-
ist human recombinant, and a DNA plasmid pVGI.1
(VEGF2)) (Fig. 2).
FDA approvals
Between 1983 and 2013, 14/77 (18 %) orphan drug des-
ignations received FDA approval representing 13 differ-
ent compounds, because canakinumab was approved for
two indications (Table 2, Fig. 1). Five drugs were ap-
proved for JIA, three for CAPS, three for uveitis, one for
familial Mediterranean fever, one for ANCA associated
vasculitis, and one for xerostomia and keratoconjunctivi-
tis sicca in Sjögren's syndrome patients (Table 2). The
first approved orphan compound for a rare rheuma-
tologic condition was pilocarpine hydrochloride for
treating xerostomia and keratoconjunctivitis in Sjögren’s
syndrome in 1998. Mean time (standard deviation) from
designation to approval was 3.9 (2.81) [range 1 … 12]
years. Divided according to drug classes, 6/14 (43 %)
FDA orphan drug approvals comprised small molecules
and 8/14 (57 %) FDA orphan drug approvals were bi-
ologics. The time between orphan drug designation
and time of approval was similar for biologics and
small molecules (Fig. 3). Most pivotal trials were random-
ized controlled trials (Table 2).Withdrawn orphan drug designations
Overall, 15/77 (19 %) orphan drug designations (14 com-
pounds) were withdrawn before approval (Table 3). The
reasons for withdrawals were not captured in the FDA
database.
Pharmacologic categories of designated orphan drugs
Designated compounds were immunomodulators, such
as immunosuppressants, immunostimulants, tolero-
gens, or compounds with unspecified immunomodula-
tory properties, Nonsteroidal anti-inflammatory drugs
(NSAIDs), expectorants, antibiotics, and angiogenic,
antiarrhythmic, diagnostic, parasympathomimetic, and
sympatholytic agents.
Design of pivotal clinical trials and endpoints leading to
FDA approval
Only one pivotal trial, i.e. the study of anakinra for the
treatment of neonatal onset inflammatory disease, was
open label (Table 2). The other 12 approved compounds
were studied for 13 indications in randomized controlled
trials in which withdrawal designs were common. Col-
chicine received approval for the treatment of familial
Mediterranean fever based on data available in the pub-
lished literature. Most clinical trials were rather small
and involved both children and adults. Studies were
either uncontrolled (i.e., anakinra) or controlled with
placebo (i.e., colchicine, rilonacept, canakinumab in both
indications, etanercept, pilocarpine, adalimumab, and
tocilizumab), sham procedure (i.e., dexamethasone intra-
vitreal implant), before after control (i.e., fluocinolone
acetonide intravitreal implant), or active control (i.e.,
meloxicam vs. naproxen, difluprednate ophthalmic solu-
tion vs. prednisolone, rituximab vs. cyclophosphamide in
a non-inferiority design). Etanercept was studied as add-
on therapy to an NSAID and/or prednisone.
Discussion
In 2013, 77 orphan drug designations for rare rheu-
matologic disorders were granted by the FDA whereof
Table 1 Drug class and indications of designated anti-rheumatic orphan drugs
Drug class Compound Designated indication according to FDA database
Biologic
Chimeric monoclonal antibody Infliximab Treatment of juvenile rheumatoid arthritis.
Treatment of giant cell arteritis.
Treatment of chronic sarcoidosis.
Rituximab For the use in combination with glucocorticoids for the
treatment of patients with Wegener’s granulomatosis (WG)
and microscopic polyangiitis (MPA).
Human monoclonal antibody Adalimumab Treatment of juvenile rheumatoid arthritis.
Canakinumab Treatment of pediatric (age 16 and under) juvenile
rheumatoid arthritis.
Treatment of cryopyrin-associated periodic syndromes.
Treatment of Tumor Necrosis Factor-receptor associated
periodic syndrome (TRAPS).
Treatment of hyperimmunoglobulinemia D and periodic
fever syndrome.
Treatment of familial mediterranean fever.
Golimumab Treatment of chronic sarcoidosis.
Treatment of sarcoidosis.
Secukinumab Adjunctive treatment of chronic non-infectious uveitis
requiring systemic immunosuppression.
Ustekinumab Treatment of chronic sarcoidosis.
Humanized monoclonal antibody Eculizumab Treatment of dermatomyositis.
Gevokizumab Treatment of Behçet disease.
Treatment of non-infectious intermediate, posterior or pan
uveitis, or chronic non-infectious anterior uveitis.
Humanized monoclonal antibody
to CD40L (IDEC-131)
Treatment of systemic lupus erythematosus.
Humanized, afucosylated IgG1 kappa
monoclonal antibody
Treatment of scleroderma.
Mepolizumab Treatment of Churg-Strauss Syndrome.
Recombinant humanized monoclonal
antibody 5c8
Treatment of systemic lupus erythematosus.
Tocilizumab Treatment of pediatric patients (age 16 years and younger)
with polyarticular-course juvenile idiopathic arthritis.
Unspecified monoclonal antibody Human anti- Tumor Necrosis Factor
alpha monoclonal antibody
Treatment of uveitis of the posterior segment of non-
infectious etiology, and uveitis of the anterior segment of
non-infectious etiology and refractory to conventional therapy.
Monoclonal antibody for immunization
against lupus nephritis
Treatment of lupus nephritis.
Fusion protein Etanercept Reduction in signs and symptoms of moderately to severely
active polyarticular-course juvenile rheumatoid arthritis in
patients who have had an inadequate response to one or
more disease-modifying anti-rheumatic drugs.
Treatment of Wegener’s granulomatosis.
Rilonacept Treatment of CIAS1-associated periodic syndromes.
Treatment of familial Mediterranean fever.
Other Anakinra Treatment of cryopyrin-associated periodic syndromes.
Hanferon Treatment of Behçet disease.
Interferon beta-1a Treatment of juvenile rheumatoid arthritis.
Interleukin-1 receptor antagonist,
human recombinant
Treatment of juvenile rheumatoid arthritis.
pVGI.1 (VEGF2) Treatment of thromboangiitis obliterans.
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Table 1 Drug class and indications of designated anti-rheumatic orphan drugs (Continued)
Small molecule 8-methoxsalen For use in conjunction with the UVAR photopheresis to
treat diffuse systemic sclerosis.
Apremilast Treatment of Behçet disease.
Bindarit Treatment of lupus nephritis.
Bromhexine Treatment of mild to moderate keratoconjunctivitis sicca
in patients with Sjögren's syndrome.
Clindamycin hydrochloride Treatment of sarcoidosis.
Colchicine Treatment of familial Mediterranean fever.
Treatment of Behçet Syndrome.
Cyclosporine (ophthalmic) Treatment of severe keratoconjunctivitis sicca associated
with Sjogren’s syndrome.
Dehydroepiandrosterone Treatment of systemic lupus erythematosus (SLE) and the
reduction in the use of steroids in steroid-dependent
SLE patients.
Dexamethasone (intravitreal implant) Treatment of non-infectious ocular inflammation of the
posterior segment in patients with intermediate, posterior,
and panuveitis.
Difluprednate (ophthalmic solution) Treatment of endogenous and traumatic anterior uveitis
and panuveitis.
Dimethyl sulfoxide Treatment of cutaneous manifestations of scleroderma.
Fluocinolone acetonide (intravitreal
implant)
Treatment uveitis involving the posterior segment of the eye.
Gammalinolenic acid Treatment of juvenile rheumatoid arthritis.
Guanethidine monosulfate Treatment of moderate to severe reflex sympathetic
dystrophy and causalgia.
Gusperimus trihydrochloride Treatment of Wegener’s granulomatosis.
Meloxicam Treatment of juvenile rheumatoid arthritis.
Methotrexate Treatment of juvenile rheumatoid arthritis.
Minocycline hydrochloride Treatment of sarcoidosis.
Nabumetone Treatment of pediatric juvenile rheumatoid arthritis.
N-acetyl-procainamide Prevention of life-threatening ventricular arrhythmias in
patients with documented procainamide-induced lupus.
Nitric oxide Diagnosis of sarcoidosis.
Pentoxifylline Treatment of Behçet disease.
Pilocarpine HCl Treatment of xerostomia and keratoconjunctivitis sicca in
Sjögren's syndrome patients.
Rofecoxib Treatment of juvenile rheumatoid arthritis.
Siponimod Treatment of polymyositis.
Sirolimus Treatment of chronic/refractory anterior noninfectious uveitis,
noninfectious intermediate uveitis, noninfectious panuveitis
and non-infectious, uveitis affecting the posterior of the
eye (NICUPS).
Thymopentin Treatment of sarcoidosis.
Other Abetimus Treatment of lupus nephritis.
Allogeneic ex-vivo expanded placental
adherent stromal cells
Treatment of thromboangiitis obliterans (Buerger’s disease).
Bone marrow-derived mononuclear cells Treatment of thromboangiitis obliterans (Buerger’s disease).
Cyclo {{(E,Z)-(2S, 3R, 4R)-3-hydroxy-4-
methyl-2-(methylamino) nona-6,8-
dienoyl}-L-2-aminobytyrl-N-methyl-glycyl-
N-methyl-L-leucyl-L-valyl-N-methyl-L-
leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-
N-methyl-L-leucyl-N-methyl-L-valyl}
Treatment and chronic control of non-infectious posterior,
intermediate and pan-uveitis.
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Table 1 Drug class and indications of designated anti-rheumatic orphan drugs (Continued)
Human gammaglobulin Treatment for juvenile rheumatoid arthritis.
Treatment of idiopathic inflammatory myopathies.
Immune globulin intravenous (IVIG) Treatment of juvenile rheumatoid arthritis.
Treatment of polymyositis/dermatomyositis.
Kre-Celazine (Oral Buffered Creatine-
Cetylated Fatty Acid Compound)
Treatment of juvenile rheumatoid arthritis joint and
related tissue inflammation in the pediatric population.
Lactobacillus brevis CD2 Treatment Behçet disease.
L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-
L-leu-L-asn-L-ser-L-ser
Treatment of neuropathic pain in patients with sarcoidosis.
Natural human lymphoblastoid
interferon-alpha
Treatment of Behçet disease.
Peptide 144 (TGF beta-1-inhibitor) Treatment of localized scleroderma.
Purified type II collagen Treatment of juvenile rheumatoid arthritis.
Unknown AI-RSA Treatment of autoimmune uveitis.
Interleukin-1 Trap Treatment of Still’s disease including juvenile rheumatoid
arthritis and adult-onset Still’s disease.
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stances. Almost every fifth designation was withdrawn,
mostly with unknown reasons. However, with etanercept
safety reasons may have played a role in withdrawal: eta-
nercept was studied in Wegener’s granulomatosis with a
higher incidence of malignancies observed in the etaner-
cept group compared with standard therapy [10, 11]. The
success rate to achieve marketing approval in rheumato-
logic orphan drug development is comparable to overall
success rates in orphan drug development, i.e. 14 % [12].
In general, failure of orphan drug applications are mainlyFig. 2 Orphan drugs for rare rheumatologic disorders: year of orphan drugattributed to the pivotal clinical trial design (e.g. choice of
endpoints and target population), inexperience in orphan
drug development of sponsors, and a low level of inter-
action with the FDA (e.g. protocol assistance) [13]. These
factors seem to be interdependent because inexperienced
sponsors may choose inadequate pivotal clinical trial
designs and may benefit most from FDA protocol assist-
ance. The reasons why compounds were withdrawn or
not approved e.g. lack of efficacy, safety issues or due to
commercially driven decisions, are not available in the
FDA database. Although, this information would be ofdesignation by technology platform
Table 2 Orphan drugs for the treatment of rare rheumatologic disorders approved by the FDA between 1983 and 2013
Compound Approved indication according
to FDA label
Pharmacologic
category
Designation
year
Approval
year
Pivotal clinical trial Reference
Study
design
N Age Study
duration
Main outcome measure
Pilocarpine
hydrochloride
Treatment of dry mouth in
patients with Sjögren’s syndrome
Cholinergic agonist 1992 1998 RCT 256 mean 57 years
(24 – 85)
12 weeks Global improvement of
dry mouth
[26]
RCT 373 mean 55 years
(21 – 84)
12 weeks Global improvement of
dry mouth
Etanercept Reduction in signs and symptoms
of moderately to severely active
polyarticular-course juvenile
rheumatoid arthritis in patients
who have had an inadequate
response to one or more disease-
modifying anti-rheumatic drugs
Tumor necrosis
factor-alpha
inhibitor
1998 1999 RCT 69 2 – 17 years 7 months JIA definition of
improvement criteria
[10]
Dexamethasone
(intravitreal implant)
Treatment of non-infectious uveitis
affecting the posterior segment of
the eye
Glucocorticoid 1998 2010 RCT 153 n/a 8 weeks Vitreous haze score and
3-line improvement from
baseline in best corrected
visual acuity
[27]
Fluocinolone acetonide
(intravitreal implant)
Treatment of chronic non-infectious
uveitis affecting the posterior segment
of the eye
Glucocorticoid 2000 2005 RCT 108 n/a 3 years Rate of recurrence of uveitis
affecting the posterior
segment of the study eye
[28]
RCT 116 n/a 3 years Rate of recurrence of
uveitis affecting the
posterior segment of the
study eye
Meloxicam For relief of the signs and symptoms
of pauciarticular or polyarticular course
juvenile rheumatoid arthritis in
patients 2 years of age or older
NSAID 2002 2005 RCT n/a ≥2 years 12 weeks ACR Pediatric 30 [29]
RCT n/a ≥2 years 12 weeks ACR Pediatric 30
Rilonacept Treatment of cryopyrin-associated
periodic syndromes
Interleukin inhibitor 2004 2008 RCT 47 n/a 24 weeks CAPS symptom score [30]
Adalimumab Treatment of juvenile idiopathic
arthritis
Tumor necrosis
factor-alpha
inhibitor
2005 2008 RCT 171 4 – 17 years 32 weeks ACR Pediatric 30 [31]
OL 32 2 – ≤ 4 years or ≥
4 years weighing
< 15 kg
120 weeks Safety
Rituximab For the use in combination with
glucocorticoids for the treatment
of patients with Wegener’s
granulomatosis and microscopic
polyangiitis
Selective
immunosuppressant
2006 2011 RCT 197 ≥15 years 18 months Birmingham Vasculitis Activity
Score for Granulomatosis
with Polyangiitis
[16]
Colchicine Treatment of familial Mediterranean
fever
Mitotic poison 2007 2009 Evidence for the efficacy was derived from the published literature. [32]
RCT 15 n/a n/a n/a
RCT 22 n/a n/a n/a
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Table 2 Orphan drugs for the treatment of rare rheumatologic disorders approved by the FDA between 1983 and 2013 (Continued)
Canakinumab Treatment of cryopyrin-associated
periodic syndromes, in adults and
children 4 years of age and older
Interleukin inhibitor 2007 2009 RCT 31 9 – 74 years 8 weeks Minimal or better for physician’s
assessment of disease activity,
assessment of skin disease,
and serum levels of C-Reactive
Protein and Serum Amyloid A
[19]
OL n/a 4 – 74 years n/a
Canakinumab Treatment of active systemic
juvenile idiopathic arthritis in
patients aged 2 through 16 years
Interleukin inhibitor 2008 2013 RCT 84 mean 8.5 years
(2 – 20)
4 weeks Adapted ACR Pediatric 30
and absence of fever
[19]
RCT 177 mean 8.5 years
(2 – 20)
n/a ACR Pediatric 30
Difluprednate
(ophthalmic solution)
Treatment of endogenous
anterior uveitis
Glucocorticoid 2008 2012 RCT 110 n/a 2 weeks Difference in anterior
chamber cell grade
[33]
RCT 90 n/a 2 weeks Difference in anterior
chamber cell grade
Anakinra Treatment of neonatal-onset
multisystem inflammatory disease
Interleukin inhibitor 2010 2012 OL 43 0.7 – 46 years 60 months disease-specific Diary
Symptom Sum Score
[34]
Tocilizumab Treatment of active polyarticular
juvenile idiopathic arthritis in
patients 2 through 16 years of age
Interleukin inhibitor 2012 2013 RCT 188 2 – 17 years 24 weeks JIA ACR 30 flare [20]
ACR Pediatric 30 American College of Rheumatology Pediatric 30 response, CAPS Cryopyrin-associated periodic syndromes, JIA Juvenile idiopathic arthritis, JIA ACR 30 flare Juvenile idiopathic arthritis American College
of Rheumatology 30 flare, JRA Juvenile rheumatoid arthritis, n/a not applicable or no information is provided in the FDA label, NSAID Nonsteroidal anti-inflammatory drugs, OL Open label, RCT Randomized controlled
trial, uncontrolled, SJIA Systemic juvenile idiopathic arthritis
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Fig. 3 Orphan drugs for rare rheumatologic disorders – time to FDA approval. a by drug class. b by disease. Lines indicate means
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unnecessary exposure to further research and should
be made publically available.
By definition, drug development in orphan diseases
is challenged by small sample sizes [5]. In addition,
disease-specific factors, such as the prevalence, disease
class, and scientific output, influence success rates in
orphan drug development [14]. Rheumatologic diseases
include complex pathomechanisms which complicates
identification of potential drug targets. Most of the desig-
nated compounds target autoimmune and subsequent in-
flammatory reactions. Particularly, immunomodulators play
a pivotal role in disease modification by modulating various
pathophysiologically relevant targets in the inflammatory
process e.g., antibodies against specific surface anti-
gens on lymphocytes, glucocorticoids that inhibit
transcription of inflammatory cytokines such as inter-
leukins and TNF-alpha, decoy receptors, or antago-
nists for receptors of inflammatory proteins. In
addition, compounds that relieve symptoms associatedwith rheumatologic diseases were designated as or-
phan drugs, such as pilocarpine-HCl which increases
lacrimal secretion and hence alleviates xerostomia and
keratoconjunctivitis sicca in Sjögren’s syndrome patients.
Nitric oxide (NO), a biomarker of airway inflammation,
received orphan drug designation for the diagnosis of
sarcoidosis. However, the diagnostic clinical trial could
not detect a difference in exhaled NO levels between pa-
tients and controls [15]. All remaining 76 orphan drug
designations for rheumatologic conditions were of thera-
peutic purpose.
Orphan drugs for rheumatologic disease hold indications
in other disease areas by targeting pathways also relevant
in other conditions. For example, rituximab, which is a
selective immunosuppressant targeting CD20 surface
proteins on B-lymphocytes, is also approved for treatment
of Non-Hodgkin’s Lymphoma and Chronic Lymphocytic
Leukemia [16]. In contrast, orphan drugs for lysosomal
storage disorders target a specific pathway that is unique
for the respective conditions. For instance, although Fabry
Table 3 Withdrawn orphan drug designations between 1983 and 2013 for compounds intended to treat rare rheumatologic disorders
Withrawn compound Designation year Designated indication according to FDA database
Dimethyl sulfoxide 1986 Cutaneous manifestations of scleroderma
Guanethidine monosulfate 1986 Moderate to severe reflex sympathetic dystrophy and causalgia
Bromhexine 1989 Mild to moderate keratoconjunctivitis sicca in patients with
Sjögren’s syndrome
Immune globulin intravenous (human) 1992 Juvenile rheumatoid arthritis
Immune globulin intravenous (human) 1992 Polymyositis/dermatomyositis
AI-RSA 1992 Autoimmune uveitis
Methotrexate 1993 Juvenile rheumatoid arthritis
Dehydroepiandrosterone 1994 Systemic lupus erythematosus (SLE) and the reduction in the use
of steroids in steroid-dependent SLE patients
Interferon beta-1a 1998 Juvenile rheumatoid arthritis
Humanized MAb (IDEC-131) to CD40L 1999 Systemic lupus erythematosus
Etanercept 1999 Wegener’s granulomatosis
pVGI.1 (VEGF2) 1999 Thromboangiitis obliterans
Infliximab 2003 Giant cell arteritis
Human Anti-tumor Necrosis factor alpha
monoclonal antibody
2003 Uveitis of the posterior segment of non-infectious etiology, and
uveitis of the anterior segment of non-infectious etiology and
refractory to conventional therapy
Golimumab 2004 Chronic sarcoidosis
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therapeutic enzyme for Fabry disease (agalsidase alfa
or beta) is different to the enzyme replacement ther-
apy in Gaucher disease (recombinant glucocerebrosi-
dase) [17, 18].
The choice for or against an orphan drug development
pathway can vary within same disease entity: both
tocilizumab and canakinumab are approved for the treat-
ment of systemic juvenile idiopathic arthritis. Of interest,
the orphan program with canakinumab consisted of two
studies with N = 261 participants followed for 4 and
48 weeks, whereas the non-orphan tocilizumab program
had only one clinical trial and involved N = 112 subjects
with a study duration of 12 weeks [19, 20]. Sample size and
design of pivotal clinical trials for the approved rheumato-
logic orphan drug indication varied. Most studies were ran-
domized placebo controlled trials which corroborates that
drug development in rare diseases is possible at a high level
of evidence. The FDA guidance for industry for the devel-
opment of drug products for the treatment of rheumatoid
arthritis recommends the use of efficacy endpoints captur-
ing clinical remission and prevention of structural damage,
suggests to limit the use of placebo both in short-term and
long-term trials, and encourages study designs with active
comparators [21]. Endpoints in clinical trials of the orphan
drugs approved for rheumatologic disorders included cat-
egorical variables such as number of attacks in familial
Mediterranean fever under colchicine, rate of recurrence of
uveitis under fluocinolone acetonid intravitreal implant,disease scores such as vitreous haze score or anterior
chamber cell grade for uveitis under difluprednate
ophthalmic emulsion or dexamethasone intravitreal im-
plant, multisystem composite disease scores, such as the
Birmingham Vasculitis Activity Score for Granulomatosis
with Polyangiitis [22] or the American College of Rheu-
matology Pediatric 30 criteria for improvement which
comprises subjective, objective and biochemical compo-
nents [23]. For the future, it would be desirable to capture
the impact of the tested intervention on patients’ needs by
including patient centered outcome measures such as the
Canadian Occupational Performance Measure as clinical
trial endpoints where possible [24]. As signals may not be-
come evident or may not be detectable in the initial small
and short clinical trials (Table 2), it is desirable to follow-
up on the long-term effectiveness and safety outcome in
systematic disease registries after drug approval. Com-
pared to oncological orphan drugs with a shorter time to
approval, orphan drug designations in rheumatologic dis-
eases seem to be either set earlier in the drug development
process or the process from designation to approval may
be slower [12]. In general, orphan drug designations are
granted during the final steps of the drug development
process [25]. Although, the orphan drug designation is
arbitrary in the drug development process, time to ap-
proval allows an approximate estimation of orphan drug
approvals of currently filed designated orphan drugs.
This quantitative analysis has several limitations. We
made the assumption that the designation of a compound
Lutz et al. Orphanet Journal of Rare Diseases  (2016) 11:60 Page 11 of 12as an orphan drug was considered a surrogate for the
intent to develop a drug for a disease. However, not all
manufacturers may seek orphan drug designation by the
FDA and information may therefore not be transparent,
e.g. due to patent considerations. The amount of designa-
tions might be prone to bias since one compound might
be designated as an orphan drug several times, e.g. inter-
leukin 1-trap and rilonacept. The true duration of the
development program may not be reflected by time to
approval because the time of orphan designation may be
arbitrary in the drug development process and, thus does
not allowing a comparison between orphan drug develop-
ment and non-orphan drug development. Data from the
European Medicine Agency data were not formally ana-
lyzed. We chose this approach, because the European
orphan legislation was only introduced in 2000. Therefore,
the European database is less comprehensive compared to
the one hosted by the FDA. However, drug development
for orphan conditions is a global effort. EMA orphan drug
designations show similar trends (data not shown). There-
fore, the present formal analysis of the FDA data and their
impact for patients around the world are considered
generalizable.
Conclusions
In conclusion, orphan drug development is challenging:
30 years of US orphan drug act delivered 14 orphan
drug programs with anti-rheumatic or supportive com-
pounds for six rare rheumatologic conditions. Although,
rarity and diversity of conditions account for the small
sizes all but one pivotal study were randomized con-
trolled trials.
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